BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Investment analysts at SunTrust Banks issued their Q4 2019 EPS estimates for BioDelivery Sciences International in a research report issued to clients and investors on Thursday, April 11th. SunTrust Banks analyst G. Gilbert anticipates that the specialty pharmaceutical company will earn $0.01 per share for the quarter. SunTrust Banks has a “Buy” rating and a $7.00 price objective on the stock. SunTrust Banks also issued estimates for BioDelivery Sciences International’s FY2020 earnings at $0.31 EPS, FY2021 earnings at $0.64 EPS, FY2022 earnings at $1.01 EPS and FY2023 earnings at $1.38 EPS.

BDSI has been the subject of a number of other research reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $5.00 target price on shares of BioDelivery Sciences International in a report on Friday, February 8th. Janney Montgomery Scott reiterated a “buy” rating and issued a $5.00 target price on shares of BioDelivery Sciences International in a report on Thursday, January 31st. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Friday, January 18th. Finally, BidaskClub upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $5.79.

Shares of BioDelivery Sciences International stock opened at $4.81 on Monday. The company has a market capitalization of $350.49 million, a PE ratio of -6.59 and a beta of 0.46. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82. BioDelivery Sciences International has a one year low of $1.70 and a one year high of $5.37.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.10). The firm had revenue of $18.03 million during the quarter, compared to analysts’ expectations of $16.15 million. BioDelivery Sciences International had a negative return on equity of 79.59% and a negative net margin of 60.87%.

Several hedge funds have recently modified their holdings of BDSI. Advisor Group Inc. lifted its stake in shares of BioDelivery Sciences International by 56.3% during the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock worth $40,000 after acquiring an additional 3,943 shares during the last quarter. Squarepoint Ops LLC bought a new stake in BioDelivery Sciences International during the 4th quarter valued at $147,000. Raymond James & Associates raised its position in BioDelivery Sciences International by 14.9% during the 4th quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock valued at $171,000 after purchasing an additional 6,000 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in BioDelivery Sciences International during the 3rd quarter valued at $255,000. Finally, Virtu Financial LLC bought a new stake in BioDelivery Sciences International during the 1st quarter valued at $300,000. 56.89% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Mark A. Sirgo sold 9,050 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $5.20, for a total transaction of $47,060.00. Following the completion of the sale, the director now directly owns 2,509,005 shares of the company’s stock, valued at approximately $13,046,826. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 23,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $5.07, for a total value of $116,610.00. Following the sale, the director now directly owns 544,187 shares of the company’s stock, valued at $2,759,028.09. The disclosure for this sale can be found here. Insiders have sold a total of 2,048,050 shares of company stock valued at $10,241,990 over the last three months. 13.26% of the stock is owned by corporate insiders.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Recommended Story: Trading Ex-Dividend

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.